Vericel Corporation (NASDAQ:VCEL) saw a significant growth in short interest in January. As of January 31st, there was short interest totalling 1,395,389 shares, a growth of 41.2% from the January 13th total of 988,219 shares. Currently, 4.4% of the company’s stock are sold short. Based on an average trading volume of 626,320 shares, the short-interest ratio is presently 2.2 days.
Large investors have recently added to or reduced their stakes in the stock. Stonepine Capital Management LLC increased its stake in Vericel Corporation by 84.1% in the fourth quarter. Stonepine Capital Management LLC now owns 1,883,800 shares of the company’s stock valued at $5,651,000 after buying an additional 860,752 shares during the period. Numeric Investors LLC acquired a new stake in Vericel Corporation during the second quarter valued at approximately $261,000. Finally, JPMorgan Chase & Co. acquired a new stake in Vericel Corporation during the second quarter valued at approximately $1,875,000. 24.32% of the stock is currently owned by institutional investors and hedge funds.
Several research analysts recently commented on the stock. Needham & Company LLC reduced their target price on shares of Vericel Corporation from $12.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday, November 9th. Piper Jaffray Companies assumed coverage on shares of Vericel Corporation in a research note on Thursday, December 22nd. They set an “overweight” rating and a $6.00 target price for the company.
Vericel Corporation (NASDAQ:VCEL) opened at 2.75 on Monday. The firm has a 50-day moving average of $2.80 and a 200 day moving average of $2.53. The company’s market capitalization is $59.11 million. Vericel Corporation has a 12-month low of $1.77 and a 12-month high of $6.69.
TRADEMARK VIOLATION NOTICE: This piece of content was originally reported by sleekmoney and is owned by of sleekmoney. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The correct version of this piece of content can be read at http://sleekmoney.com/vericel-corporation-vcel-short-interest-update/1657153.html.
Vericel Corporation Company Profile
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/vericel-corporation-vcel-short-interest-update/1657153.html
Receive News & Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related companies with MarketBeat.com's FREE daily email newsletter.